Longer-term organ abnormalities confirmed in some post-hospitalised COVID patients

23 September 2023

A study looking at the longer-term impact of COVID-19 has found that nearly a third of patients displayed abnormalities in multiple organs five months after infection, some of which have been shown through previous work to be evidence of tissue damage.

Magnetic resonance imaging (MRI) scans of patients on the trial showed a higher burden of abnormal findings involving the lungs, brain and kidneys compared to controls. Lung abnormalities were significantly higher (almost 14-fold higher) among patients discharged from hospital for COVID-19 than in the control group, while abnormal findings involving the brain and kidneys were three and two times higher respectively.

The extent of abnormalities on MRI was often influenced by the severity of the COVID-19 infection the patients had experienced and their age, as well as co-morbidities.

The findings, published in The Lancet Respiratory Medicine, are part of the C-MORE (Capturing the MultiORgan Effects of COVID-19) study. C-MORE, a multi-centre MRI follow-up study of 500 post-hospitalised COVID-19 patients, is a key element of the national PHOSP-COVID platform, led by the University of Leicester, which is investigating the long-term effects of COVID-19 on hospitalised patients. This paper presents the results of an interim analysis of 259 post-hospitalised COVID-19 patients and 52 controls.

The C-MORE study is being led by researchers from the University of Oxford’s Radcliffe Department of Medicine and is supported by the NIHR Oxford Biomedical Research Centre (BRC) and the NIHR Oxford Health BRC, as well as the BHF Oxford Centre for Research Excellence and Wellcome Trust.

The participants, who were recruited across 13 sites in the UK, underwent MRI scans covering the heart, brain, lungs, liver and kidneys an average of five months after discharge from hospital. They also had blood tests and completed questionnaires.

Dr Betty Raman, who is leading the C-MORE study, said: “We found that nearly one in three patients had an excess burden of multiorgan abnormalities on MRI relative to controls. At five months after hospital discharge for COVID-19, patients showed a high burden of abnormalities involving the lungs, brain and kidneys compared to our non-COVID-19 controls. The age of the individual, severity of acute COVID-19 infection, as well as co-morbidities, were significant factors in determining who had organ injury at follow-up.”

The study found that while some organ-specific symptoms correlated with the imaging evidence of organ injury – for example, chest tightness and cough with lung MRI abnormalities - not all symptoms could be directly linked to MRI-detected anomalies.

The levels of damage to the heart and liver in the former hospitalised COVID-19 patients were similar to those in the control group.

The paper also confirmed that multi-organ MRI abnormalities were more common among post-hospitalised patients who reported severely impaired physical and mental health after COVID-19, as previously described by the PHOSP-COVID study investigators.

“What we are seeing is that people with multiorgan pathology on MRI – that is, they had more than two organs affected - were four times more likely to report severe and very severe mental and physical impairment. Our findings also highlight the need for longer term multidisciplinary follow-up services focused on pulmonary and extrapulmonary health (kidneys, brain and mental health), particularly for those hospitalised for COVID-19,” Dr Raman said.

She added: “These findings are the result of extensive collaborative efforts by investigators across the UK. We are incredibly grateful to patients and the public who have participated in this study.”
Professor Chris Brightling of the NIHR Leicester BRC, who is leading the PHOSP-COVID study said: “This detailed study of whole-body imaging confirms that changes in multiple organs is seen months after being hospitalised for COVID-19. The PHOSP-COVID study is working on understanding why this happens and how we can develop tests and new treatments for long COVID”.

Notes to editors

The National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC) is based at the Oxford University Hospitals NHS Foundation Trust and run in partnership with the University of Oxford.

The mission of the NIHR is to improve the health and wealth of the nation through research. We do this by:

  • funding high quality, timely research that benefits the NHS, public health and social care;
  • investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
  • partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
  • attracting, training and supporting the best researchers to tackle complex health and social care challenges;
  • collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
  • funding applied global health research and training to meet the needs of the poorest people in low- and middle-income countries.

NIHR is funded by the Department of Health and Social Care. Its work in low- and middle-income countries is principally funded through UK Aid from the UK government.

Chris McIntyre
Communications Manager (Research and Innovation), University of Oxford
christopher.mcintyre@admin.ox.ac.uk tel (direct): 01865 270 046 or tel (News Office): 01865 280528

About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the seventh year running, and number 3 in the QS World Rankings 2024. At the heart of this success are the twin-pillars of our ground-breaking research and innovation and our distinctive educational offer.
Oxford is world-famous for research and teaching excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research alongside our personalised approach to teaching sparks imaginative and inventive insights and solutions.
Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 300 new companies since 1988. Over a third of these companies have been created in the last five years. The university is a catalyst for prosperity in Oxfordshire and the United Kingdom, contributing £15.7 billion to the UK economy in 2018/19, and supports more than 28,000 full time jobs.